为众生谋健康
AI 驱动 mRNA 创新药物平台

One Health For All
AI-Powered mRNA Drug Platform

澄实生物致力于利用人工智能与 mRNA 技术平台,开发针对肿瘤和传染病的创新疗法与疫苗,让更多患者获得前沿治疗。

TheraRNA leverages AI and mRNA technology platforms to develop innovative therapies and vaccines targeting cancer and infectious diseases.

了解核心技术 Explore our technology
SCROLL
0
授权专利
Patents Granted
0
SCI 论文
SCI Papers
0
核心团队
Core Team
H100
GPU 算力集群
GPU Cluster
2-8°C
冻干常温保存
Cold Chain Free
我们的使命
Our mission
澄实生物专注于 AI 驱动的 mRNA 全栈药物研发,致力于为全球患者提供更有效、更可及的创新疗法。
TheraRNA is committed to AI-driven full-stack mRNA drug development, delivering more effective and accessible therapies to patients worldwide.

我们相信,人工智能与免疫学的深度融合将彻底改变药物研发的范式。从 AI 新生抗原预测到自研 LNP 递送系统,从 mRNA 分子设计到 GMP 规模化量产——澄实生物构建了全链条自主可控的技术闭环,打通从算法到产品的完整路径。

We believe the deep integration of artificial intelligence and immunology will fundamentally transform drug development. From AI neoantigen prediction to proprietary LNP delivery systems, from mRNA molecular design to GMP mass production — TheraRNA has built a fully self-controlled technology closed loop, bridging algorithm to product.

了解更多 Read more
AI+mRNA全栈平台
治疗领域
Therapeutic areas
聚焦肿瘤免疫治疗、耐药菌感染和动物健康三大领域,以 mRNA 技术平台为核心驱动。
Focused on oncology immunotherapy, drug-resistant bacterial infections, and animal health, powered by our mRNA technology platform.
研发管线
Pipeline

利用 mRNA 技术平台的强大通用性和 AI 算法的高效迭代能力,构建覆盖多适应症的丰富管线。

Leveraging the versatility of mRNA platforms and AI-driven rapid iteration to build a diversified pipeline across multiple indications.

0
在研品种
Pipeline Products
0
三甲医院合作
Top Hospital Partners
0
肿瘤客观缓解率
Oncology ORR
10亿
年产能(剂)
Annual Capacity (doses)
查看完整管线Explore our pipeline
新闻动态
Latest news
了解澄实生物的最新研发进展、合作动态和行业资讯。
Stay updated with TheraRNA's latest R&D progress, partnerships, and industry insights.
查看全部新闻View all news